High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Practice Guidelines as Topic
After controlling for known prognostic factors in this nonrandomized analysis of two large independent data sets, women receiving HDC versus SDC for metastatic breast cancer have a similar short-term probability of survival, and might have a modestly higher long-term probability of survival.